Comparative Pharmacology
Head-to-head clinical analysis: MIDAZOLAM HYDROCHLORIDE AUTOINJECTOR versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDAZOLAM HYDROCHLORIDE AUTOINJECTOR versus PAXIPAM.
MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midazolam is a short-acting benzodiazepine that potentiates GABA-A receptor activity by binding to the benzodiazepine site, enhancing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, amnestic, anticonvulsant, and muscle relaxant effects.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
10 mg intramuscularly once via autoinjector for acute seizure control.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.8–6.4 hours (mean ~3 hours) in healthy adults; prolonged in elderly, obese, hepatic impairment (up to 15–20 hours), and critical illness.
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Renal excretion of metabolites (glucuronide conjugates) accounts for approximately 90% of elimination; less than 1% excreted unchanged; minimal fecal excretion (< 5%).
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine